271 related articles for article (PubMed ID: 26239045)
41. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
Saito M; Yasui-Furukori N; Uno T; Takahata T; Sugawara K; Munakata A; Tateishi T
Br J Clin Pharmacol; 2005 Mar; 59(3):302-9. PubMed ID: 15752376
[TBL] [Abstract][Full Text] [Related]
42. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
Sugimoto M; Furuta T; Shirai N; Kajimura M; Hishida A; Sakurai M; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2004 Oct; 76(4):290-301. PubMed ID: 15470328
[TBL] [Abstract][Full Text] [Related]
43. Population pharmacokinetics of voriconazole and the role of CYP2C19 genotype on treatment optimization in pediatric patients.
Hu L; Huang S; Huang Q; Huang J; Feng Z; He G
PLoS One; 2023; 18(9):e0288794. PubMed ID: 37695751
[TBL] [Abstract][Full Text] [Related]
44. Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.
Hamadeh IS; Klinker KP; Borgert SJ; Richards AI; Li W; Mangal N; Hiemenz JW; Schmidt S; Langaee TY; Peloquin CA; Johnson JA; Cavallari LH
Pharmacogenet Genomics; 2017 May; 27(5):190-196. PubMed ID: 28306618
[TBL] [Abstract][Full Text] [Related]
45. Invasive Aspergillus infection requiring lobectomy in a CYP2C19 rapid metabolizer with subtherapeutic voriconazole concentrations.
Hicks JK; Gonzalez BE; Zembillas AS; Kusick K; Murthy S; Raja S; Gordon SM; Hanna R
Pharmacogenomics; 2016 May; 17(7):663-7. PubMed ID: 27143031
[TBL] [Abstract][Full Text] [Related]
46. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing.
Dolton MJ; Mikus G; Weiss J; Ray JE; McLachlan AJ
J Antimicrob Chemother; 2014 Jun; 69(6):1633-41. PubMed ID: 24554646
[TBL] [Abstract][Full Text] [Related]
47. Population estimation regarding the effects of cytochrome P450 2C19 and 3A5 polymorphisms on zonisamide clearance.
Okada Y; Seo T; Ishitsu T; Wanibuchi A; Hashimoto N; Higa Y; Nakagawa K
Ther Drug Monit; 2008 Aug; 30(4):540-3. PubMed ID: 18641551
[TBL] [Abstract][Full Text] [Related]
48. CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?
Owusu Obeng A; Egelund EF; Alsultan A; Peloquin CA; Johnson JA
Pharmacotherapy; 2014 Jul; 34(7):703-18. PubMed ID: 24510446
[TBL] [Abstract][Full Text] [Related]
49. Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review.
Lee J; Ng P; Hamandi B; Husain S; Lefebvre MJ; Battistella M
Ann Pharmacother; 2021 Apr; 55(4):509-529. PubMed ID: 32772568
[TBL] [Abstract][Full Text] [Related]
50. A pharmacokinetic/pharmacodynamic analysis of a standard voriconazole regimen in different CYP2C19 genotypes by Monte Carlo simulation.
Liao S; Ge T; Zhu L; Zhao Y; Yang J; Xu G
Pharmazie; 2015 May; 70(5):306-9. PubMed ID: 26062298
[TBL] [Abstract][Full Text] [Related]
51. Association of
Zhao T; Shen H; Zhang HL; Feng J; Liu SM; Wang TT; Li HJ; Yu LH
Pharmacogenomics; 2023 Feb; 24(3):141-151. PubMed ID: 36718992
[No Abstract] [Full Text] [Related]
52. Association of CYP2B6, CYP3A5, and CYP2C19 genetic polymorphisms with sibutramine pharmacokinetics in healthy Korean subjects.
Kim KA; Song WK; Park JY
Clin Pharmacol Ther; 2009 Nov; 86(5):511-8. PubMed ID: 19693007
[TBL] [Abstract][Full Text] [Related]
53. CYP2C19 is involved in the effect of Wuzhi tablet (
Yuan F; Liang X; Chen X; Qin X; Tan C; Wang L
Pharmazie; 2020 Nov; 75(11):559-564. PubMed ID: 33239129
[TBL] [Abstract][Full Text] [Related]
54. Effects of genetic polymorphisms of CYP2C19*2/*3 and MDR1 C3435T on the pharmacokinetics of lansoprazole in healthy Chinese subjects.
Zhang YX; Wei SJ; Yang XY; Zhang WP; Wang XY; Dang HW
Int J Clin Pharmacol Ther; 2014 Oct; 52(10):850-5. PubMed ID: 25109411
[TBL] [Abstract][Full Text] [Related]
55. Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation.
Miura M; Niioka T; Kagaya H; Saito M; Hayakari M; Habuchi T; Satoh S
J Clin Pharm Ther; 2011 Apr; 36(2):208-16. PubMed ID: 21366650
[TBL] [Abstract][Full Text] [Related]
56. Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics.
Rengelshausen J; Banfield M; Riedel KD; Burhenne J; Weiss J; Thomsen T; Walter-Sack I; Haefeli WE; Mikus G
Clin Pharmacol Ther; 2005 Jul; 78(1):25-33. PubMed ID: 16003289
[TBL] [Abstract][Full Text] [Related]
57. Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and N-desmethylclobazam in japanese patients with epilepsy.
Saruwatari J; Ogusu N; Shimomasuda M; Nakashima H; Seo T; Tanikawa K; Tsuda Y; Nishimura M; Nagata R; Yasui-Furukori N; Kaneko S; Ishitsu T; Nakagawa K
Ther Drug Monit; 2014 Jun; 36(3):302-9. PubMed ID: 24345815
[TBL] [Abstract][Full Text] [Related]
58. Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test.
Desta Z; Modak A; Nguyen PD; Lemler SM; Kurogi Y; Li L; Flockhart DA
J Pharmacol Exp Ther; 2009 Apr; 329(1):297-305. PubMed ID: 19136640
[TBL] [Abstract][Full Text] [Related]
59. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections.
Lamoureux F; Duflot T; Woillard JB; Metsu D; Pereira T; Compagnon P; Morisse-Pradier H; El Kholy M; Thiberville L; Stojanova J; Thuillez C
Int J Antimicrob Agents; 2016 Feb; 47(2):124-31. PubMed ID: 26775563
[TBL] [Abstract][Full Text] [Related]
60. High voriconazole target-site exposure after approved sequence dosing due to nonlinear pharmacokinetics assessed by long-term microdialysis.
Kirbs C; Kluwe F; Drescher F; Lackner E; Matzneller P; Weiss J; Zeitlinger M; Kloft C
Eur J Pharm Sci; 2019 Apr; 131():218-229. PubMed ID: 30731238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]